About Us

At Adiso, we create medicines to treat inflammatory diseases, to improve the lives of patients and their families. We believe that current therapeutic approaches are often inadequate to halt disease progression or run the risk of burdening the patient with significant safety concerns.

To tackle these challenges, we are advancing an innovative pipeline of multi-modal small molecules all with novel mechanisms of action and a precision therapeutic approach. Our approach to developing therapeutics delivered locally to the site of inflammation is clinically and scientifically differentiated.

ADS051 is a first-in-class, oral, gut-restricted modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis that has completed a Phase 1b MAD clinical trial and will be moving into Phase 2 development later this year. Adiso is also developing ADS032, a first-in-class small molecule that acts as a dual inflammasome inhibitor (NLRP3 & NLRP1) and is in advanced pre-clinical development for the treatment of respiratory and dermal inflammation.

More About Us

Leadership Team

Scott Megaffin
Chief Executive Officer

Renu Gupta, M.D.
Chief Medical Officer

Bharat Dixit, PhD
Chief Technology Officer

Srikar Guntaka, M.D.
Medical Director

Jillian Chapas-Reed
Head of Clinical Operations

Shannon Foley
Head of Finance

Brandan Hillerich, PhD
Head of Business Development

Andrew Peranick, CFA
Head of Corporate Strategy

Board of Directors

Isaac Cheng, M.D.

Jason Dinges, JD, PhD

Robert Lisicki

Scott Megaffin

More About the Leadership Team

Our Development Pipeline

First-In-Class Small Molecule Modulator of Neutrophil Trafficking and Activation

Preclinical

IND Enabling

Phase 1

Phase 2

Phase 3

ADS051

Ulcerative Colitis

ADS051 is an oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis. ADS051 blocks MRP2-mediated neutrophil trafficking into and FPR1-mediated neutrophil activation within the colonic lumen. Unlike currently available therapies, this addresses neutrophil-mediated tissue damage, a hallmark of UC pathology. In a healthy volunteer study and MAD patient study, ADS051 was safe and well tolerated and restricted to the gut with limited systemic exposure.

Portfolio of First-In-Class Small Molecule Inhibitor of the NLRP3 and 1 Inflammasomes

Preclinical

IND Enabling

Phase 1

Phase 2

Phase 3

ADS032

Respiratory Inflammation

ADS032 is a novel small molecule inhibitor that blocks two types of inflammasomes simultaneously, NLRP1 and NLRP3 – the innate immune system’s receptors and first line sensors of pathogens and other danger signals. Chronic activation of NLRP1 and NLPR3 is directly implicated in a wide range of inflammation-triggered conditions across multiple organ systems. By targeting both NLRP3 and NLRP1, ADS032 may provide a comprehensive anti-inflammatory approach across a range of diseases. Our development candidates are focused on Respiratory and Dermal inflammation.

Contact Us